High-resolution imaging to check if tumors are completely removed during surgery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the effectiveness of high-resolution PET-CT imaging during surgery to ensure complete removal of tumors in patients with various cancers, including breast, prostate, and thyroid cancers. By using a radiotracer and imaging the excised tissue, the study aims to provide immediate feedback on whether additional tissue needs to be removed, potentially reducing the need for further treatments. The study will also compare the imaging results with traditional microscopic analysis to assess accuracy and safety. The goal is to improve surgical outcomes and reduce patient stress and costs associated with delayed results.

Why it matters

Who can join: the full rules

A. Inclusion Criteria:

* able to understand treatment protocol and informed consent form
* estimated by the investigator to be compliant for study participation

  1\. Fulfilling all group-specific inclusion criteria:
* confirmed breast cancer with an indication to undergo breast conserving surgery
* confirmed prostate cancer with an indication to undergo resective surgeryprostatectomy;
* confirmed thyroid lesion with an indication to undergo resective surgery;
* confirmed parathyroid adenoma with an indication to undergo resective surgery;
* suspected basal cell carcinoma, squamous cell carcinoma or melanoma with an indication to undergo resective surgery;
* suspected lesion in genitourinary sites (including bladder cancer, renal pelvis and ureter carcinoma, adrenal cortical carcinoma and renal cell carcinoma) with an indication to undergo resective surgery;
* suspected lesion in the head \& neck region with an indication to undergo resective surgery;
* confirmed primary or secondary hepatobiliary cancer with an indication to undergo resective surgery;
* patients undergoing biopsy after metabolic active lesions were detected on a PET scan.
* suspected neuro-endocrine malignancies with an indication to undergo resective surgery.
* suspected brain tumor with an indication to undergo resective surgery.
* Suspected malignant and benign gastrointestinal lesions with an indication to undergo resective surgery.
* suspected malignant thoracovascular lesions with an indication to undergo resective surgery

B. Exclusion Criteria:

* general or local contra-indications for resective surgery;
* in case of FDG-based PET tracers: a blood glucose level over 200 mg/dL on the day of surgery;
* pregnancy or lactation;
* participation in other clinical studies with a radiation exposure of more than 1 mSv in the past year.

Where it's running

• AZ Maria Middelares
  Ghent, Oost Vlaanderen, Belgium Recruiting

Study contacts

• Study coordinator: Tessa Van Oostveldt
• Email: klinische.studies@mijnziekenhuis.be
• Phone: +3292468000

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using brodalumab to treat immune-related side effects from cancer therapy

  This study is testing if brodalumab can help cancer patients who are having immune-related side effects from their immunotherapy treatment feel better.

  Recruiting Phase 1 Columbia University · New York, New York · NCT06673329

• Using blood tests to assess early treatment response in cancer patients

  This study is testing if blood tests that look for cancer DNA can help doctors see how well treatment is working for patients with different types of solid tumors.

  Recruiting Washington University School of Medicine · St Louis, Missouri · NCT04354064

• Effects of Atezolizumab on Cancer Patients with Sensitive Tumor DNA or RNA

  This study is testing if atezolizumab can help cancer patients with certain tumor types that show they might respond well to the treatment.

  Recruiting Phase 2 British Columbia Cancer Agency · Vancouver, British Columbia and 1 other locations · NCT04273061

• High-precision detection of leftover cancer using a liquid-biopsy platform (SHERLOCK)

  This project will test whether sensitive blood and other fluid tests for circulating tumor DNA can find leftover cancer (minimal residual disease) in adults treated with curative intent for breast, lung, melanoma, gynecologic, or genitourinary cancers.

  Recruiting University Health Network, Toronto · Toronto, Ontario · NCT07524114

• Riluzole to prevent thinking and memory problems during chemotherapy

  This pilot trial tests whether riluzole can prevent thinking and memory problems in adults with cancer receiving anthracycline- or platinum-based chemotherapy.

  Recruiting Phase 2 University of California, Irvine · Orange, California · NCT07447050

• Predicting Immunotherapy Response from Live Tumor Biopsies

  This project will try to see if analyzing live tumor biopsy samples kept in their 3D environment can predict whether people with advanced solid tumors will respond to immunotherapy.

  Recruiting at 7 sites Elephas · Fort Smith, Arkansas and 7 other locations · NCT07327489

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.